Monitor for the appointment of a new Chief Legal Officer, which could signal strategic priorities. The Arbutus and Pfizer litigation outcomes are material to the contingent payments but the amounts are small relative to Moderna's market cap.
MRNA drugs
MRNA drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Moderna entered into a Transitional Services and Retirement Agreement with Chief Legal Officer Shannon Thyme Klinger, who will retire effective March 31, 2027. She will remain employed through that date to assist with the CLO search and litigation transitions, receiving $1.63M in severance plus contingent litigation success payments of up to $8.0M. The departure is a planned retirement with a named transition period and no replacement named yet.
Key Facts
- Shannon Thyme Klinger, Chief Legal Officer, will retire effective March 31, 2027
- She will continue employment through a transition period to assist with CLO search and litigation matters
- Severance pay of $1,628,300 (12 months base salary plus target bonus) paid biweekly over 12 months
- Contingent litigation success payments: $2.5M if Moderna prevails in Arbutus case; up to $5.5M from Pfizer litigation recovery
- COBRA premium assistance until September 30, 2028
- 2026 bonus eligible at target $771,300 multiplied by corporate performance factor
- No replacement CLO has been named yet
Financial Impact
Total severance and benefits of at least $1.63M, plus up to $8.0M in contingent litigation payments; immaterial relative to $100.6B market cap
Risk Factors
- No replacement CLO named yet; search is ongoing
- Contingent litigation payments depend on favorable outcomes in Arbutus and Pfizer cases
- Early termination for Cause or resignation before March 31, 2027 would forfeit severance and litigation payments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001682852-26-000205 |
| Document: mrna-20261113.htm | 0001682852-26-000205 |
| Document: 0001682852-26-000205-index-headers.html | 0001682852-26-000205 |
| Document: 0001682852-26-000205-index.html | 0001682852-26-000205 |
| Document: 0001682852-26-000205.txt | 0001682852-26-000205 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Viewing Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers